Rhumbline Advisers Anavex Life Sciences Corp. Call Options Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVXL
# of Institutions
195Shares Held
32MCall Options Held
1.33MPut Options Held
875K-
Black Rock Inc. New York, NY6.39MShares$68.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$55.1 Million0.0% of portfolio
-
State Street Corp Boston, MA2.95MShares$31.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.02MShares$21.8 Million0.0% of portfolio
-
Nwam LLC Mercer Island, WA1.02MShares$11 Million0.83% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $840M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...